Consumable product portfolio a natural extension for STERIS’s Healthcare Customers

耗材产品组合是STERIS医疗保健客户群体的自然延伸

Compelling financial benefits: expected to be accretive to top-line growth, margins and adjusted earnings

令人信服的财务效益：预计将对收入增长、利润率和调整后收益产生增厚作用

Anticipated to close by December 31, 2026

预计于2026年12月31日前完成

DUBLIN, IRELAND, Oct. 12, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that STERIS Corporation, a wholly owned subsidiary of the Company, has signed a definitive agreement to acquire Xodus Medical, Inc., a specialty surgical products business based in Pennsylvania, and certain related affiliates (“Xodus Medical”), for $2.1 billion at closing.

爱尔兰都柏林，2026年10月12日（环球电讯社）——STERIS plc（纽约证券交易所代码：STE）（“STERIS”或“公司”）今日宣布，其全资子公司STERIS Corporation已签署一项最终协议，将以21亿美元的交割对价收购总部位于宾夕法尼亚州的专业外科产品企业Xodus Medical, Inc.及其某些关联附属公司（统称“Xodus Medical”）。

STERIS anticipates that the transaction will generate cash tax benefits with a net present value of approximately $300 million, resulting in a net purchase price of approximately $1.8 billion. The purchase price is subject to customary adjustments, with additional potential earnout consideration of up to $150 million based on the achievement of specified post-closing performance targets in calendar 2028.

STERIS预计，该交易将产生净现值约为3亿美元的现金税收优惠，从而使净购买价格约为18亿美元。购买价格须受惯例调整约束，并可能根据2028年日历年度内实现特定交割后绩效目标的情况，支付最高达1.5亿美元的额外或有对价。

Annual revenue of Xodus Medical in calendar 2026 is anticipated to be approximately $245 million, with adjusted EBIT of approximately $135 million..

预计Xodus Medical在2026日历年度的年收入约为2.45亿美元，调整后息税前利润（EBIT）约为1.35亿美元。

“Xodus Medical’s product portfolio complements and expands STERIS’s offering, particularly by adding consumables used in the operating room. Its focus on products that make surgery safer aligns closely with our MISSION TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD,” said Dan Carestio, President and Chief Executive Officer of STERIS.

“Xodus Medical 的产品组合补充并扩展了 STERIS 的产品供应，尤其是增加了手术室使用的耗材。其专注于提升手术安全性的产品，与我们‘帮助客户创造更健康、更安全的世界’的使命高度契合。”STERIS 总裁兼首席执行官 Dan Carestio 表示。

“The business has demonstrated an ability to grow at double-digit rates with its specialty product portfolio, a steady stream of new products, and a highly effective commercial team. We look forward to welcoming the Xodus Medical team to STERIS and working together to enhance our service to our Customers and value for our shareholders.”.

“该企业凭借其专业产品组合、源源不断的新品推出以及高效能的商业团队，展现了实现两位数增长的能力。我们期待欢迎Xodus Medical团队加入STERIS，携手提升对客户的服务并为股东创造更大价值。”

“Xodus Medical is an established provider of solutions that measurably improve surgical patient safety,” said Craig Kaforey, Chief Executive Officer of Xodus Medical. “Joining a global leader like STERIS marks an exciting new chapter for our company and allows us to deliver even greater value to our Customers.

“Xodus Medical 是一家成熟的解决方案提供商，其方案能够切实提升手术患者的安全性，”Xodus Medical 首席执行官 Craig Kaforey 表示。“加入像 STERIS 这样的全球领导者行列，为我们公司开启了令人振奋的新篇章，也使我们能够为客户创造更大的价值。”

For our employees, this partnership opens incredible opportunities for professional growth and development across our entire organization.”.

对于我们的员工而言，此次合作为整个组织内的专业成长与发展开启了非凡的机遇。

Under the terms of the agreement, STERIS Corporation will acquire all the equity of Xodus Medical. The transaction is expected to be financed primarily with debt and is anticipated to close by December 31, 2026, subject to customary closing conditions and regulatory approvals. STERIS will provide revised fiscal 2027 outlook inclusive of Xodus Medical after closing..

根据协议条款，STERIS公司将收购Xodus Medical的全部股权。该交易预计主要通过债务融资，并计划在满足惯例交割条件和获得监管批准的前提下，于2026年12月31日前完成交割。交割完成后，STERIS将提供包含Xodus Medical在内的修订后2027财年业绩展望。

Advisors

顾问

Goldman Sachs & Co. LLC is serving as exclusive financial advisor to STERIS, and Jones Day is serving as legal counsel. J.P. Morgan is serving as exclusive financial advisor to Xodus Medical, and Morgan, Lewis & Bockius LLP is serving as legal counsel.

高盛有限责任公司担任STERIS的独家财务顾问，琼斯戴律师事务所担任其法律顾问。摩根大通担任Xodus Medical的独家财务顾问，摩根·刘易斯·博克ius律师事务所担任其法律顾问。

About STERIS

关于 STERIS

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. For more information, visit .

STERIS 是一家全球领先的提供商，专注于提供以感染预防为重点、支持患者护理的产品与服务。我们通过在全球范围内提供创新的医疗保健和生命科学产品与服务，帮助客户创造一个更健康、更安全的世界。欲了解更多信息，请访问。

www.steris.com

www.steris.com

.

。

About Xodus Medical

关于 Xodus Medical

Founded in 1993 and headquartered near Pittsburgh, Pennsylvania, Xodus Medical is a leading developer and manufacturer of innovative medical devices dedicated to Making Surgery Safer™. The company's comprehensive portfolio of proprietary surgical safety technologies, including its flagship Pink Pad® patient positioning systems, serves hospitals worldwide.

Xodus Medical 成立于1993年，总部位于宾夕法尼亚州匹兹堡附近，是一家领先的创新医疗器械开发商和制造商，致力于“让手术更安全™”。公司拥有全面的专有手术安全技术产品组合，包括其旗舰产品 Pink Pad® 患者体位系统，服务于全球各地的医院。

Xodus Medical has established itself as a trusted partner to healthcare professionals and a recognized leader in perioperative patient safety. For more information, visit .

Xodus Medical 已确立其作为医疗保健专业人士值得信赖的合作伙伴的地位，并成为围手术期患者安全领域的公认领导者。欲了解更多信息，请访问。

www.xodusmedical.com

www.xodusmedical.com

.

。

STERIS Contact

STERIS 联系方式

Julie Winter, Vice President Investor Relations and Corporate Communications

朱莉·温特，投资者关系与企业传播副总裁

julie_winter@steris.com

julie_winter@steris.com

Non-GAAP Financial Measures

非公认会计准则财务指标

Projected Xodus Medical Adjusted EBIT is a non-GAAP financial measure and should not be considered a substitute for results prepared in accordance with U.S. GAAP. The Company presents this measure to provide investors with additional insight into the financial information used by management and the Board of Directors in evaluating the acquisition of Xodus Medical..

预计的Xodus Medical调整后EBIT是一项非GAAP财务指标，不应被视为根据美国GAAP编制的业绩指标的替代。公司列报该指标旨在为投资者提供额外信息，以便更好地了解管理层和董事会在评估收购Xodus Medical时所采用的财务信息。

As used in this release, Xodus Medical Adjusted EBIT represents Xodus Medical’s projected operating income of $121 million for the full calendar year ending December 31, 2026, adjusted for approximately $14 million of charges substantially consisting of a royalty arrangement that was terminated during 2026..

在本公告中，Xodus Medical 调整后息税前利润（Adjusted EBIT）是指 Xodus Medical 截至 2026 年 12 月 31 日止整个日历年的预计营业利润为 1.21 亿美元，并针对约 1,400 万美元的费用进行了调整，该等费用主要由一项于 2026 年终止的特许权使用费安排构成。

Projected Xodus Medical Adjusted EBIT is a forward-looking non-GAAP financial measure that reflects expectations regarding Xodus Medical's operating results for the fiscal year ending December 31, 2026. This measure should not be considered in isolation or as a substitute for comparable U.S. GAAP financial measures.

预计的Xodus Medical调整后EBIT是一项前瞻性的非GAAP财务指标，反映了对Xodus Medical截至2026年12月31日财政年度经营业绩的预期。该指标不应孤立地看待，也不应作为可比美国GAAP财务指标的替代。

Readers are cautioned not to place undue reliance on forward-looking non-GAAP financial measures..

提醒读者不要过度依赖前瞻性的非GAAP财务指标。

Cautionary Statement Regarding Forward-Looking Information

关于前瞻性信息的警示性声明

This release contains statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations.

本次发布包含涉及影响或与 STERIS 或其行业、产品或活动相关的某些趋势、预期、预测、估计或其他前瞻性信息的陈述，旨在符合 1995 年《私人证券诉讼改革法案》及其他法律法规对“前瞻性陈述”所提供的保护资格。

Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology.

前瞻性陈述仅反映作出该陈述之日的情况，并可通过使用“可能”、“将”、“预期”、“相信”、“预计”、“计划”、“估计”、“规划”、“目标”、“预测”、“展望”、“影响”、“潜力”、“信心”、“改善”、“乐观”、“实现”、“订单”、“未完成订单”、“有信心”、“趋势”和“寻求”等前瞻性术语，或此类术语的否定形式、其他变体或类似术语来识别。

These forward-looking statements are based on management’s current expectations, estimates or forecasts about STERIS’s businesses, the industries in which it operates and current beliefs and assumptions of management and are subject to uncertainty and changes in circumstances. Readers of this release should understand that these statements are not guarantees of performance or results..

这些前瞻性陈述基于管理层对STERIS业务、其所处行业的当前预期、估计或预测，以及管理层当前的信念和假设，并受不确定性和情况变化的影响。本新闻稿的读者应理解，这些陈述并非对业绩或结果的保证。

Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those set forth in this release. No assurances can be provided as to any result or the timing of any outcome regarding matters described in STERIS’s securities filings or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, cost reductions, business strategies, earnings or revenue trends or future financial results.

许多因素可能导致实际结果与前瞻性陈述中的结果存在重大差异，包括但不限于本新闻稿中列出的因素。对于STERIS在证券备案文件中描述的事项，或涉及任何监管行动、行政程序、政府调查、诉讼、警告信、成本削减、业务战略、盈利或收入趋势或未来财务结果的任何结果或其发生时间，均无法作出任何保证。

Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S.

其他可能导致实际结果与前瞻性陈述存在重大差异的潜在风险和不确定性包括但不限于：(a) 美国可能实施的任何立法、法规或命令（包括但不限于任何新的贸易法规或命令）对 STERIS 及其运营的影响。

administration or Congress, or of any responses thereto by non-U.S. governments, (b) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins, (c) the potential of international unrest, military conflicts, economic downturns, currency fluctuations and cybersecurity events and any resulting effects on STERIS’s anticipated growth, performance or other results, (d) changes in healthcare policy or government or other third-party payor reimbursement levels, (e) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, may de.

政府或国会，或非美国政府对此作出的任何回应；(b) 运营成本、定价压力（包括但不限于因通货膨胀导致的压力）、客户流失及业务中断（包括但不限于在维持与员工、客户、委托人或供应商关系方面的困难）超出预期，从而导致利润率侵蚀；(c) 国际动荡、军事冲突、经济衰退、货币波动及网络安全事件的潜在风险，以及由此对 STERIS 预期增长、业绩或其他结果产生的任何影响；(d) 医疗政策的变化或政府及其他第三方付款人报销水平的变化；(e) 遵守法律、法院裁决、认证、法规或其他监管行动的可能性，或任何未决或威胁诉讼的结果，可能会。

Readers are cautioned not to place undue reliance on any forward-looking statements included in this release, which speak only as of the date hereof. STERIS undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable law..

提醒读者不要过度依赖本新闻稿中包含的任何前瞻性陈述，这些陈述仅反映截至本文发布之日的情况。除非适用法律另有要求，STERIS 不承担因新信息、未来发展或其他原因而更新或修订任何前瞻性陈述的义务。